CN119032082A - N-{[(s)-{[3-(4-氯苯基)-4-苯基-4,5-二氢-1h-吡唑-1-基][4-(三氟甲基)苯磺酰胺基]亚甲基}氨基]亚氨甲酰基}乙酰胺的结晶形式 - Google Patents

N-{[(s)-{[3-(4-氯苯基)-4-苯基-4,5-二氢-1h-吡唑-1-基][4-(三氟甲基)苯磺酰胺基]亚甲基}氨基]亚氨甲酰基}乙酰胺的结晶形式 Download PDF

Info

Publication number
CN119032082A
CN119032082A CN202380020969.2A CN202380020969A CN119032082A CN 119032082 A CN119032082 A CN 119032082A CN 202380020969 A CN202380020969 A CN 202380020969A CN 119032082 A CN119032082 A CN 119032082A
Authority
CN
China
Prior art keywords
temperature
compound
degrees
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380020969.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·麦卡锡
M·帕特尔
周俊
程成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN119032082A publication Critical patent/CN119032082A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380020969.2A 2022-02-09 2023-02-08 N-{[(s)-{[3-(4-氯苯基)-4-苯基-4,5-二氢-1h-吡唑-1-基][4-(三氟甲基)苯磺酰胺基]亚甲基}氨基]亚氨甲酰基}乙酰胺的结晶形式 Pending CN119032082A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263267734P 2022-02-09 2022-02-09
US63/267,734 2022-02-09
PCT/CA2023/050163 WO2023150874A1 (en) 2022-02-09 2023-02-08 Crystalline forms of n-{[(s)-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1h-pyrazol-1-yl][4-(trifluoromethyl)benzene sulfonamido]methylidene}amino] methanimidoyl}acetamide

Publications (1)

Publication Number Publication Date
CN119032082A true CN119032082A (zh) 2024-11-26

Family

ID=87563337

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380020969.2A Pending CN119032082A (zh) 2022-02-09 2023-02-08 N-{[(s)-{[3-(4-氯苯基)-4-苯基-4,5-二氢-1h-吡唑-1-基][4-(三氟甲基)苯磺酰胺基]亚甲基}氨基]亚氨甲酰基}乙酰胺的结晶形式

Country Status (5)

Country Link
US (1) US20250188038A1 (https=)
EP (1) EP4476200A4 (https=)
JP (1) JP2025506454A (https=)
CN (1) CN119032082A (https=)
WO (1) WO2023150874A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196646A1 (en) * 2015-06-04 2016-12-08 The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services Cannabinoid receptor mediating compounds

Also Published As

Publication number Publication date
EP4476200A4 (en) 2026-01-14
EP4476200A1 (en) 2024-12-18
JP2025506454A (ja) 2025-03-11
US20250188038A1 (en) 2025-06-12
WO2023150874A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
US8703967B2 (en) Crystal form of sunitinib malate
CN103459381B (zh) 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸晶型及其生产方法
JP2015180679A (ja) ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
KR20140138941A (ko) 상피 성장 인자 수용체 키나제 억제제의 염
CN102070618B (zh) 一种化合物及其晶体
US20240174669A1 (en) Crystalline forms of a parp1 inhibitor
WO2016124067A1 (zh) 一种周期素依赖性蛋白激酶抑制剂的羟乙基磺酸盐、其结晶形式及制备方法
TW201040161A (en) Crystalline polymorphic form 631
TW202308991A (zh) 三苯化合物之固體形式
CA2628330A1 (en) F,g,h,i and k crystal forms of imatinib mesylate
JP2018516946A (ja) ヒストン脱アセチル化阻害剤の結晶形態
WO2016155578A1 (zh) 达格列净的新晶型及其制备方法
WO2023138681A1 (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
US20250129042A1 (en) Crystalline forms of 3-(5-(2-hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1h-indole-7-carbonitrile
WO2016188444A1 (zh) 一种尿酸转运蛋白抑制剂的钠盐及其结晶形式
CN119032082A (zh) N-{[(s)-{[3-(4-氯苯基)-4-苯基-4,5-二氢-1h-吡唑-1-基][4-(三氟甲基)苯磺酰胺基]亚甲基}氨基]亚氨甲酰基}乙酰胺的结晶形式
TW201008935A (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
US10934273B2 (en) Crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-N-methylpicolinamide
JP6656505B2 (ja) オービットアジン−フマル酸塩、水和物、結晶形及びその調製方法
EA006245B1 (ru) Гидрохлорид 4-[4-(2-пирролилкарбонил)-1-пиперазинил]-3-трифторметилбензоилгуанидина
TW202003467A (zh) Urat-1抑制劑的新型鹽形式
CN113149998B (zh) 2-吲哚啉螺环酮类化合物或其盐、溶剂合物的无定形形式或结晶形式
US20060194833A1 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
WO2025240706A1 (en) Crystalline forms of kras g12d inhibitor and uses thereof
TW202545931A (zh) 3-(5-(2-羥基-2-甲基丙氧基)-6甲基吡-2-基)-1h-吲哚-7-甲腈之晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination